KR910019971A - 신규한 아미노 보호 그룹 - Google Patents

신규한 아미노 보호 그룹 Download PDF

Info

Publication number
KR910019971A
KR910019971A KR1019910007472A KR910007472A KR910019971A KR 910019971 A KR910019971 A KR 910019971A KR 1019910007472 A KR1019910007472 A KR 1019910007472A KR 910007472 A KR910007472 A KR 910007472A KR 910019971 A KR910019971 A KR 910019971A
Authority
KR
South Korea
Prior art keywords
alkyl
substituted
hydrogen
formula
compound
Prior art date
Application number
KR1019910007472A
Other languages
English (en)
Inventor
오토 웨이겔 렐란드
Original Assignee
리로이 휘테커
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리로이 휘테커, 일라이 릴리 앤드 캄파니 filed Critical 리로이 휘테커
Publication of KR910019971A publication Critical patent/KR910019971A/ko

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • C07C231/10Preparation of carboxylic acid amides from compounds not provided for in groups C07C231/02 - C07C231/08
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C07D205/085Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a nitrogen atom directly attached in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/448Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D463/00Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D463/02Preparation
    • C07D463/06Preparation from compounds already containing the ring or condensed ring systems, e.g. by dehydrogenation of the ring, by introduction, elimination or modification of substituents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

내용 없음

Description

신규한 아미노 보호 그룹
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (6)

  1. 하기 일반식 (2)의 화합물을 일반식 HNRR0의 아민과 반응시킴을 포함하는 하기 일반식(1)화합물의 제조방법:
    상기식에서 R및 R0는 개별적으로 수소 C1내지 C6알킬 그룹이거나 또는 이들이 결합된 질소 원자와 함께 C2내지 C7질소- 함유 고리(상기 고리는 임의로 하나 이상의 C1내지 C6알킬 및/또는 C1내지 C6치환된 알킬 그룹으로 치환된다)를 형성하고; Q및 Q′는개별적으로 수소, C1내지 C6알킬이거나 또는 함께 구조식-CH=CH-CH=CH-의 2가 라디칼을 형성하고; R*는 유기 잔기이다.
  2. 하기 일반식(1)의 화합물과 산을 반응시킨 다음 화합물(A)와 화합물 (B)를 분리시킴을 포함하는 하기 일반식(A) 및 (B)화합물의 제조방법:
    상기식에서, Q및 Q′는개별적으로 수소 C1내지 C6알킬이거나 또는 함께 구조식-CH=CH-CH=CH-의 2가 라디칼을 형성하고; 상기식에서 R및 R0는 개별적으로 수소 C1내지 C6알킬그룹이거나 또는 이들이 결합된 질소 원자와 함께 C2내지 C7질소- 함유 고리(상기 고리는 임의로 하나 이상의 C1내지 C6알킬 및/또는 C1내지 C6치환된 알킬 그룹으로 치환된다)를 형성하고 이들은 함께 광학적으로 순수한 형태에서 적어도 하나의 비대칭 중심을 갖고;R*ε는 적어도 하나의 비대칭 중심을 함유하는 광학적으로 순수한 형태의 유기 잔기이며; R는 라세미 형태임을 제외하고 R*ε에 대해서 상기 정의한 바와 같은 유기 잔기이다.
  3. 하기 일반식(1)의 화합물:
    상기식에서 R및 R0는 개별적으로 수소 C1내지 C6알킬그룹이거나 또는 이들이 결합된 질소 원자와 함께 C2내지 C7질소- 함유 고리(상기 고리는 임의로 하나 이상의 C1내지 C6알킬 및/또는 C1내지 C6치환된 알킬 그룹으로 치환된다)를 형성하고; Q및 Q′는개별적으로 수소 C1내지 C6알킬이거나 또는 함께 구조식-CH=CH-CH=CH-의 2가 라디칼을 형성하고; R**는 일반식
    〔여기에서,A는 C1내지 C6알킬, C1내지 C6치환된 알킬, -S-( C1내지 C6알킬)CO2R″또는 -CH2(C1내지 C6알킬)CO2R″(여기에서 R″는 수소 또는 카복시- 보호 그룹이다)이고; A′는 수소, 마이드- 보호그룹 또는 일반식 -CH2CO2R″의 그룹이며; 또는
    A및 A′는 함께 일반식
    (여기에서, R2는 수소 또는 카복시-보호그룹이고; X는 황, -CH2-, 또는 산소이며; R1은 수소, 하이드록시, 할로, C1내지 C6알콕시, C1내지 C6알킬, C1내지 C6치환된 알킬, C1내지 C6알킬티오, C1내지 C6치환된 알킬티오, C7내지 C12페닐알킬, C7내지 C12치환된 페닐 또는 치환된 페닐이다)의 그룹; 일반식-COR3(이때 R3는 수소, C1내지 C6알킬, C1내지 C6치환된 알킬, C7내지 C12페닐알킬, C7내지 C12치환된 페닐알킬, 페닐, 치환된 페닐, 아니모, (일치환된) 아미노 또는 (이치환된)아미노이다)의 그룹; 일반식-COR4(이때 R4는 수소, C1내지 C6알킬, C1내지 C6치환된 알킬, C7내지 C12페닐알킬,7내지 C12치환된 페닐알킬, 페닐, 치환된 페닐 또는 카복시- 보호 그룹이다)의 그룹을 형성한다〕의 그룹이다.
  4. 하기 일반식의 화합물;
    상기식에서, R″는 수소 또는 카복시 보호그룹이다.
  5. 하기 일반식의 화합물:
    상기식에서, R″는 수소 또는 카복시 보호그룹이다.
  6. 하기 구조식의 화합물:
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019910007472A 1990-05-14 1991-05-09 신규한 아미노 보호 그룹 KR910019971A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52345590A 1990-05-14 1990-05-14
US07/523,455 1990-05-14

Publications (1)

Publication Number Publication Date
KR910019971A true KR910019971A (ko) 1991-12-19

Family

ID=24085088

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910007472A KR910019971A (ko) 1990-05-14 1991-05-09 신규한 아미노 보호 그룹

Country Status (7)

Country Link
EP (1) EP0457512A2 (ko)
JP (1) JPH04226952A (ko)
KR (1) KR910019971A (ko)
CA (1) CA2041897A1 (ko)
HU (1) HUT57706A (ko)
IE (1) IE911611A1 (ko)
IL (1) IL98072A0 (ko)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3905966A (en) * 1973-06-18 1975-09-16 Lilly Co Eli Cephalosporin cleavage process
DE2714655A1 (de) * 1977-04-01 1978-10-05 Bayer Ag Verfahren zur herstellung von hydantoinen
US4937331A (en) * 1988-03-25 1990-06-26 President And Fellows Of Harvard College Chiral azetidinone epoxides

Also Published As

Publication number Publication date
CA2041897A1 (en) 1991-11-15
IE911611A1 (en) 1991-11-20
JPH04226952A (ja) 1992-08-17
EP0457512A2 (en) 1991-11-21
EP0457512A3 (ko) 1994-01-19
HU911555D0 (en) 1991-11-28
IL98072A0 (en) 1992-06-21
HUT57706A (en) 1991-12-30

Similar Documents

Publication Publication Date Title
NO901300D0 (no) Behandling og forbindelser.
DE69705480D1 (de) Verwendung von Oestrogenagonisten und -antagonisten zur Herstellung eines Medikaments zur Behandlung von Atherosklerose, unabhängig von Lipidsenkung
DE3781716D1 (de) Mittel zur ortsspezifischen alkylierung.
IS4108A (is) 5'-deoxy-5-fluorytidines með viðtengdum N-Oxycarbonyl-hópum og aðferð til framleiðslu þeirra
FI893751A0 (fi) Kemiska foereningar.
DK0593641T3 (da) Fremgangsmåde til fremstilling af derivater af baccatin III og 10-desacetyl-baccatin III
PT733621E (pt) Novos derivados de imidazole e processo para a sua preparacao
FI971227A (fi) Pyramidinyylipyratsolijohdannaisia
KR880012590A (ko) 신규 함질소 화합물
ES2008962A6 (es) Proceso para la preparacion de nuevos compuestos de 2-guanidinotiazol
DE69423529D1 (de) Arzneizusammensetzungen enthaltend Argatrobananaloge
KR910019971A (ko) 신규한 아미노 보호 그룹
DE3472104D1 (en) N-substituted ûbis(hydroxymethyl)-methyl¨-isoquinoline derivatives, process for preparing them and pharmaceutical compositions containing them
SE8303913D0 (sv) Heterocykliska foreningar
ATE149494T1 (de) Benzopyranderivate und verfahren zu deren herstellung
DK432086D0 (da) Fremgangsmaade til fremstilling af beta-lactamforbindelser eller saltederaf
HUT48586A (en) Process for production of derivatives of 1,4-disubstituated piperidinil and medical preparatives containing these substances
ATE30718T1 (de) Herstellung von 1-benzyl azetidin-3-ol und von dem entsprechenden halid acid.
ATE76067T1 (de) Dihydropyridinether, verfahren zu ihrer herstellung und ihre verwendung.
ATE156487T1 (de) Mercapto-acetamid-derivate
KR880012688A (ko) 자외선 경화형 수지 조성물
NZ221004A (en) 2,6-piperazinediones and pharamceutical compositions
FI844186A0 (fi) Bis(substituerad metyl) -metylisokinolinderivat och foerfarande foer framstaellning daerav.
SE8000138L (sv) Nya 3-cyklopentan-1,2'(1'h)-naftalen-derivat, framstellning derav och lekemedel innehallande desamma
KR830001207A (ko) 치환 피로리디닐-벤조인산 유도체의 제조방법

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid